Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Average Price Target from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have received a consensus rating of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $28.83.

Several research analysts recently weighed in on IMNM shares. Stephens initiated coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target for the company. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Finally, Piper Sandler lowered their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th.

Immunome Stock Performance

NASDAQ IMNM opened at $10.54 on Friday. Immunome has a fifty-two week low of $8.97 and a fifty-two week high of $30.96. The firm has a market capitalization of $657.88 million, a P/E ratio of -1.30 and a beta of 1.83. The stock has a 50-day simple moving average of $12.01 and a two-hundred day simple moving average of $13.20.

Insider Activity at Immunome

In related news, insider Robert Lechleider purchased 15,805 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the transaction, the insider now directly owns 15,805 shares in the company, valued at approximately $149,831.40. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CTO Philip Tsai acquired 21,000 shares of the stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the acquisition, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 102,862 shares of company stock valued at $978,045. 8.60% of the stock is owned by company insiders.

Institutional Trading of Immunome

Several large investors have recently made changes to their positions in IMNM. Quest Partners LLC acquired a new stake in Immunome during the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Immunome in the second quarter worth about $97,000. Arizona State Retirement System boosted its position in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after acquiring an additional 918 shares during the last quarter. AQR Capital Management LLC grew its stake in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after acquiring an additional 4,129 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Immunome in the 3rd quarter valued at about $219,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.